MALT Lymphoma Symptoms

This article looks at MALT lymphoma symptoms, MALT lymphoma being a subtype of lymphoma. 'Lymphoma' is an umbrella term that loosely refers to several dozen independent categorical types and subtypes of cancers of the lymphatic system.

 

MALT is an acronym. It stands for:

Mucosa
Associated
Lymphatic
Tissue

Thus, MALT lymphomas are non-Hodgkin's lymphomas in which the cancerous lymphocytes gather in areas where there is mucosa tissue (stomach or GI tract, lungs, thyroid, etc). That said, 'MALT lymphoma' is no longer a lymphoma classification; rather, MALT lymphomas are now considered extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue-type. However, for the present article and for the sake of simplicity and understanding we will use the former term of MALT lymphoma.

It is broadly divided into gastric MALT lymphomas and non-gastric MALT lymphomas.

Unlike many other cancers, the cause of most cases of MALT lymphomas that arise in the stomach appears to be infectious agents, specifically one known as H. pylori. The disease is also not uncommon in people with autoimmune disorders

Because of the infectious nature of many MALT lymphomas, treatment with antibiotics alone has proven to be very effective.

MALT Lymphoma Symptoms

The general, non-specific MALT lymphoma symptoms include:

  • Stomach pains
  • Ulcers
  • Pain or discomfort in the abdominal area

Systemic symptoms,also known as B symptoms (such as fever and fatigue), are not common symptoms in people with MALT lymphomas.

Sources

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap